Featured by Medical University of South Carolina — MUSC Hollings Cancer Center researcher Leonardo Ferreira, Ph.D., and Indee Labs recently received a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Small Business Innovation Research (SBIR) grant to accelerate the development of human T-cell therapies.

Press Release — Indee Labs today announced the addition of three of the largest pharmaceutical companies, multiple biotechnology companies as well as Stanford's Cell Therapy Clinic and Moffitt Cancer Center, to participate in its Early Access Program.

Press Release — The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the µVS Delivery System^TM to insert transgenes for CAR-T and TCR-T cell products at clinical scale at a fraction of the cost of the current approaches using viruses with improved T cell function relative to electroporation.

Press Release — With funding from NIAID, our goal is to apply our novel, non-viral delivery platform, the µVS Delivery System^TM, to engineer antigen-specific T_regs and demonstrate their utility as a therapeutic to prevent GvHD in preclinical models and as a scalable alternative to viral- and electroporation-based cell manufacturing.